Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Trace Amine-Associated Receptor 1 Agonist Modulates Mismatch Negativity-Like Responses in Mice.

Aleksandrov AA, Knyazeva VM, Volnova AB, Dmitrieva ES, Polyakova NV, Gainetdinov RR.

Front Pharmacol. 2019 May 3;10:470. doi: 10.3389/fphar.2019.00470. eCollection 2019.

2.

The TAAR5 agonist α-NETA causes dyskinesia in mice.

Aleksandrov AA, Polyakova NV, Vinogradova EP, Gainetdinov RR, Knyazeva VM.

Neurosci Lett. 2019 Apr 12;704:208-211. doi: 10.1016/j.neulet.2019.04.028. [Epub ahead of print]

PMID:
30986441
3.

Comparative analysis of the influence of a high-fat/high-carbohydrate diet on the level of anxiety and neuromotor and cognitive functions in Wistar and DAT-KO rats.

Apryatin SA, Shipelin VA, Trusov NV, Mzhelskaya KV, Evstratova VS, Kirbaeva NV, Soto JS, Fesenko ZS, Gainetdinov RR, Gmoshinski IV.

Physiol Rep. 2019 Feb;7(4):e13987. doi: 10.14814/phy2.13987.

4.

Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium.

Fedorenko OY, Golimbet VE, Ivanova SА, Levchenko А, Gainetdinov RR, Semke AV, Simutkin GG, Gareeva АE, Glotov АS, Gryaznova A, Iourov IY, Krupitsky EM, Lebedev IN, Mazo GE, Kaleda VG, Abramova LI, Oleichik IV, Nasykhova YA, Nasyrova RF, Nikolishin AE, Kasyanov ED, Rukavishnikov GV, Timerbulatov IF, Brodyansky VM, Vorsanova SG, Yurov YB, Zhilyaeva TV, Sergeeva AV, Blokhina EA, Zvartau EE, Blagonravova AS, Aftanas LI, Bokhan NА, Kekelidze ZI, Klimenko TV, Anokhina IP, Khusnutdinova EK, Klyushnik TP, Neznanov NG, Stepanov VA, Schulze TG, Kibitov АО.

Mol Psychiatry. 2019 Jan 21. doi: 10.1038/s41380-019-0354-z. [Epub ahead of print] Review.

PMID:
30664668
5.

Behavioral characterization of DAT-KO rats and evidence of asocial-like phenotypes in DAT-HET rats: The potential involvement of norepinephrine system.

Adinolfi A, Zelli S, Leo D, Carbone C, Mus L, Illiano P, Alleva E, Gainetdinov RR, Adriani W.

Behav Brain Res. 2019 Feb 1;359:516-527. doi: 10.1016/j.bbr.2018.11.028. Epub 2018 Nov 22.

PMID:
30472113
6.

In vivo voltammetric evidence that locus coeruleus activation predominantly releases norepinephrine in the infralimbic cortex: Effect of acute ethanol.

Deal AL, Mikhailova MA, Grinevich VP, Weiner JL, Gainetdinov RR, Budygin EA.

Synapse. 2019 Apr;73(4):e22080. doi: 10.1002/syn.22080. Epub 2018 Nov 22.

PMID:
30447016
7.

Activation of trace amine-associated receptor 1 attenuates schedule-induced polydipsia in rats.

Sukhanov I, Dorotenko A, Dolgorukova A, Hoener MC, Gainetdinov RR, Bespalov AY.

Neuropharmacology. 2019 Jan;144:184-192. doi: 10.1016/j.neuropharm.2018.10.034. Epub 2018 Oct 24.

PMID:
30366004
8.

Novel translational rat models of dopamine transporter deficiency.

Leo D, Sukhanov I, Gainetdinov RR.

Neural Regen Res. 2018 Dec;13(12):2091-2093. doi: 10.4103/1673-5374.241453. No abstract available.

9.

Real-Time Accumbal Dopamine Response to Negative Stimuli: Effects of Ethanol.

Mikhailova MA, Deal AL, Grinevich VP, Bonin KD, Gainetdinov RR, Budygin EA.

ACS Chem Neurosci. 2019 Apr 17;10(4):1986-1991. doi: 10.1021/acschemneuro.8b00272. Epub 2018 Oct 17.

PMID:
30289684
10.

Behavioral Effects of a Potential Novel TAAR1 Antagonist.

Lam VM, Mielnik CA, Baimel C, Beerepoot P, Espinoza S, Sukhanov I, Horsfall W, Gainetdinov RR, Borgland SL, Ramsey AJ, Salahpour A.

Front Pharmacol. 2018 Sep 4;9:953. doi: 10.3389/fphar.2018.00953. eCollection 2018.

11.

Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397.

Espinoza S, Leo D, Sotnikova TD, Shahid M, Kääriäinen TM, Gainetdinov RR.

Front Pharmacol. 2018 Jun 21;9:645. doi: 10.3389/fphar.2018.00645. eCollection 2018.

12.

Trace Amines and Their Receptors.

Gainetdinov RR, Hoener MC, Berry MD.

Pharmacol Rev. 2018 Jul;70(3):549-620. doi: 10.1124/pr.117.015305. Review.

PMID:
29941461
13.

Dopamine D2 Receptor Supersensitivity as a Spectrum of Neurotoxicity and Status in Psychiatric Disorders.

Kostrzewa RM, Wydra K, Filip M, Crawford CA, McDougall SA, Brown RW, Borroto-Escuela DO, Fuxe K, Gainetdinov RR.

J Pharmacol Exp Ther. 2018 Sep;366(3):519-526. doi: 10.1124/jpet.118.247981. Epub 2018 Jun 19.

PMID:
29921706
14.

Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases.

Schwartz MD, Canales JJ, Zucchi R, Espinoza S, Sukhanov I, Gainetdinov RR.

Expert Opin Ther Targets. 2018 Jun;22(6):513-526. doi: 10.1080/14728222.2018.1480723. Epub 2018 Jun 5. Review.

PMID:
29798691
15.

The Effects of Chronic Amitriptyline on Zebrafish Behavior and Monoamine Neurochemistry.

Meshalkina DA, Kysil EV, Antonova KA, Demin KA, Kolesnikova TO, Khatsko SL, Gainetdinov RR, Alekseeva PA, Kalueff AV.

Neurochem Res. 2018 Jun;43(6):1191-1199. doi: 10.1007/s11064-018-2536-5. Epub 2018 May 8.

PMID:
29740748
16.

Identification of TAAR5 Agonist Activity of Alpha-NETA and Its Effect on Mismatch Negativity Amplitude in Awake Rats.

Aleksandrov AA, Knyazeva VM, Volnova AB, Dmitrieva ES, Korenkova O, Espinoza S, Gerasimov A, Gainetdinov RR.

Neurotox Res. 2018 Oct;34(3):442-451. doi: 10.1007/s12640-018-9902-6. Epub 2018 May 1.

PMID:
29713997
17.

Trace Amine-Associated Receptor 1 Modulates the Locomotor and Sensitization Effects of Nicotine.

Sukhanov I, Dorofeikova M, Dolgorukova A, Dorotenko A, Gainetdinov RR.

Front Pharmacol. 2018 Apr 6;9:329. doi: 10.3389/fphar.2018.00329. eCollection 2018.

18.

Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models.

Zabegalov KN, Kolesnikova TO, Khatsko SL, Volgin AD, Yakovlev OA, Amstislavskaya TG, Alekseeva PA, Meshalkina DA, Friend AJ, Bao W, Demin KA, Gainetdinov RR, Kalueff AV.

Eur J Pharmacol. 2018 Jun 15;829:129-140. doi: 10.1016/j.ejphar.2018.04.003. Epub 2018 Apr 5. Review.

PMID:
29627310
19.

Interplay between the key proteins of serotonin system in SSRI antidepressants efficacy.

Kulikov AV, Gainetdinov RR, Ponimaskin E, Kalueff AV, Naumenko VS, Popova NK.

Expert Opin Ther Targets. 2018 Apr;22(4):319-330. doi: 10.1080/14728222.2018.1452912. Epub 2018 Apr 4. Review.

PMID:
29542343
20.

Behavioral Phenotyping of Dopamine Transporter Knockout Rats: Compulsive Traits, Motor Stereotypies, and Anhedonia.

Cinque S, Zoratto F, Poleggi A, Leo D, Cerniglia L, Cimino S, Tambelli R, Alleva E, Gainetdinov RR, Laviola G, Adriani W.

Front Psychiatry. 2018 Feb 22;9:43. doi: 10.3389/fpsyt.2018.00043. eCollection 2018.

21.

Rational design, chemical synthesis and biological evaluation of novel biguanides exploring species-specificity responsiveness of TAAR1 agonists.

Guariento S, Tonelli M, Espinoza S, Gerasimov AS, Gainetdinov RR, Cichero E.

Eur J Med Chem. 2018 Feb 25;146:171-184. doi: 10.1016/j.ejmech.2018.01.059. Epub 2018 Feb 4.

PMID:
29407948
22.

Novelty-related behavior of young and adult dopamine transporter knockout rats: Implication for cognitive and emotional phenotypic patterns.

Adinolfi A, Carbone C, Leo D, Gainetdinov RR, Laviola G, Adriani W.

Genes Brain Behav. 2018 Apr;17(4):e12463. doi: 10.1111/gbb.12463. Epub 2018 Mar 22.

PMID:
29406596
23.

Pronounced Hyperactivity, Cognitive Dysfunctions, and BDNF Dysregulation in Dopamine Transporter Knock-out Rats.

Leo D, Sukhanov I, Zoratto F, Illiano P, Caffino L, Sanna F, Messa G, Emanuele M, Esposito A, Dorofeikova M, Budygin EA, Mus L, Efimova EV, Niello M, Espinoza S, Sotnikova TD, Hoener MC, Laviola G, Fumagalli F, Adriani W, Gainetdinov RR.

J Neurosci. 2018 Feb 21;38(8):1959-1972. doi: 10.1523/JNEUROSCI.1931-17.2018. Epub 2018 Jan 18.

24.

TAAR5 receptor agonist affects sensory gating in rats.

Aleksandrov AA, Dmitrieva ES, Volnova AB, Knyazeva VM, Gerasimov AS, Gainetdinov RR.

Neurosci Lett. 2018 Feb 14;666:144-147. doi: 10.1016/j.neulet.2017.12.053. Epub 2017 Dec 27.

PMID:
29288046
25.

The after-hours circadian mutant has reduced phenotypic plasticity in behaviors at multiple timescales and in sleep homeostasis.

Maggi S, Balzani E, Lassi G, Garcia-Garcia C, Plano A, Espinoza S, Mus L, Tinarelli F, Nolan PM, Gainetdinov RR, Balci F, Nieus T, Tucci V.

Sci Rep. 2017 Dec 19;7(1):17765. doi: 10.1038/s41598-017-18130-2.

26.

Human Accelerated Regions and Other Human-Specific Sequence Variations in the Context of Evolution and Their Relevance for Brain Development.

Levchenko A, Kanapin A, Samsonova A, Gainetdinov RR.

Genome Biol Evol. 2018 Jan 1;10(1):166-188. doi: 10.1093/gbe/evx240. Review.

27.

Psychedelic Drugs in Biomedicine.

Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV.

Trends Pharmacol Sci. 2017 Nov;38(11):992-1005. doi: 10.1016/j.tips.2017.08.003. Epub 2017 Sep 22. Review.

PMID:
28947075
28.

Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges.

Berry MD, Gainetdinov RR, Hoener MC, Shahid M.

Pharmacol Ther. 2017 Dec;180:161-180. doi: 10.1016/j.pharmthera.2017.07.002. Epub 2017 Jul 16. Review.

29.

No effect of C1473G polymorphism in the tryptophan hydroxylase 2 gene on the response of the brain serotonin system to chronic fluoxetine treatment in mice.

Bazhenova EY, Sinyakova NA, Kulikova EA, Kazarinova IA, Bazovkina DV, Gainetdinov RR, Kulikov AV.

Neurosci Lett. 2017 Jul 13;653:264-268. doi: 10.1016/j.neulet.2017.05.070. Epub 2017 Jun 1.

PMID:
28579486
30.

Recombinant Adeno-Associated Virus-mediated rescue of function in a mouse model of Dopamine Transporter Deficiency Syndrome.

Illiano P, Bass CE, Fichera L, Mus L, Budygin EA, Sotnikova TD, Leo D, Espinoza S, Gainetdinov RR.

Sci Rep. 2017 Apr 18;7:46280. doi: 10.1038/srep46280.

31.

Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons.

Bono F, Savoia P, Guglielmi A, Gennarelli M, Piovani G, Sigala S, Leo D, Espinoza S, Gainetdinov RR, Devoto P, Spano P, Missale C, Fiorentini C.

Mol Neurobiol. 2018 Feb;55(2):1054-1067. doi: 10.1007/s12035-016-0376-3. Epub 2017 Jan 14.

PMID:
28092083
32.

Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy.

Polanco MJ, Parodi S, Piol D, Stack C, Chivet M, Contestabile A, Miranda HC, Lievens PM, Espinoza S, Jochum T, Rocchi A, Grunseich C, Gainetdinov RR, Cato AC, Lieberman AP, La Spada AR, Sambataro F, Fischbeck KH, Gozes I, Pennuto M.

Sci Transl Med. 2016 Dec 21;8(370):370ra181. doi: 10.1126/scitranslmed.aaf9526.

PMID:
28003546
33.

Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.

Tonelli M, Espinoza S, Gainetdinov RR, Cichero E.

Eur J Med Chem. 2017 Feb 15;127:781-792. doi: 10.1016/j.ejmech.2016.10.058. Epub 2016 Oct 27.

PMID:
27823885
34.

Hit-to-Lead Optimization of Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists with a Diphenylmethane-Scaffold: Design, Synthesis, and Biological Study.

Chiellini G, Nesi G, Sestito S, Chiarugi S, Runfola M, Espinoza S, Sabatini M, Bellusci L, Laurino A, Cichero E, Gainetdinov RR, Fossa P, Raimondi L, Zucchi R, Rapposelli S.

J Med Chem. 2016 Nov 10;59(21):9825-9836. Epub 2016 Oct 21.

PMID:
27731647
35.

A Caenorhabditis elegans model to study dopamine transporter deficiency syndrome.

Illiano P, Lanzo A, Leo D, Paglione M, Zampi G, Gainetdinov RR, Di Schiavi E.

Eur J Neurosci. 2017 Jan;45(1):207-214. doi: 10.1111/ejn.13366. Epub 2016 Sep 2.

PMID:
27519790
36.

Optogenetically-induced tonic dopamine release from VTA-nucleus accumbens projections inhibits reward consummatory behaviors.

Mikhailova MA, Bass CE, Grinevich VP, Chappell AM, Deal AL, Bonin KD, Weiner JL, Gainetdinov RR, Budygin EA.

Neuroscience. 2016 Oct 1;333:54-64. doi: 10.1016/j.neuroscience.2016.07.006. Epub 2016 Jul 13.

37.

Cross-hemispheric dopamine projections have functional significance.

Fox ME, Mikhailova MA, Bass CE, Takmakov P, Gainetdinov RR, Budygin EA, Wightman RM.

Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):6985-90. doi: 10.1073/pnas.1603629113. Epub 2016 Jun 13.

38.

Dopamine transporter mutant animals: a translational perspective.

Efimova EV, Gainetdinov RR, Budygin EA, Sotnikova TD.

J Neurogenet. 2016 Mar;30(1):5-15. doi: 10.3109/01677063.2016.1144751. Review.

39.

G protein-coupled receptor kinases as regulators of dopamine receptor functions.

Gurevich EV, Gainetdinov RR, Gurevich VV.

Pharmacol Res. 2016 Sep;111:1-16. doi: 10.1016/j.phrs.2016.05.010. Epub 2016 May 10. Review.

40.

Genetic and environmental modulation of neurodevelopmental disorders: Translational insights from labs to beds.

Homberg JR, Kyzar EJ, Scattoni ML, Norton WH, Pittman J, Gaikwad S, Nguyen M, Poudel MK, Ullmann JF, Diamond DM, Kaluyeva AA, Parker MO, Brown RE, Song C, Gainetdinov RR, Gottesman II, Kalueff AV.

Brain Res Bull. 2016 Jul;125:79-91. doi: 10.1016/j.brainresbull.2016.04.015. Epub 2016 Apr 23. Review.

PMID:
27113433
41.

Understanding autism and other neurodevelopmental disorders through experimental translational neurobehavioral models.

Homberg JR, Kyzar EJ, Nguyen M, Norton WH, Pittman J, Poudel MK, Gaikwad S, Nakamura S, Koshiba M, Yamanouchi H, Scattoni ML, Ullman JF, Diamond DM, Kaluyeva AA, Parker MO, Klimenko VM, Apryatin SA, Brown RE, Song C, Gainetdinov RR, Gottesman II, Kalueff AV.

Neurosci Biobehav Rev. 2016 Jun;65:292-312. doi: 10.1016/j.neubiorev.2016.03.013. Epub 2016 Apr 2. Review.

PMID:
27048961
42.

Increased context-dependent conditioning to amphetamine in mice lacking TAAR1.

Sukhanov I, Caffino L, Efimova EV, Espinoza S, Sotnikova TD, Cervo L, Fumagalli F, Gainetdinov RR.

Pharmacol Res. 2016 Jan;103:206-14. doi: 10.1016/j.phrs.2015.11.002. Epub 2015 Dec 2.

PMID:
26640076
43.

Rapid Conversion of Fibroblasts into Functional Forebrain GABAergic Interneurons by Direct Genetic Reprogramming.

Colasante G, Lignani G, Rubio A, Medrihan L, Yekhlef L, Sessa A, Massimino L, Giannelli SG, Sacchetti S, Caiazzo M, Leo D, Alexopoulou D, Dell'Anno MT, Ciabatti E, Orlando M, Studer M, Dahl A, Gainetdinov RR, Taverna S, Benfenati F, Broccoli V.

Cell Stem Cell. 2015 Dec 3;17(6):719-734. doi: 10.1016/j.stem.2015.09.002. Epub 2015 Oct 29.

44.

In-vivo pharmacology of Trace-Amine Associated Receptor 1.

Lam VM, Espinoza S, Gerasimov AS, Gainetdinov RR, Salahpour A.

Eur J Pharmacol. 2015 Sep 15;763(Pt B):136-42. doi: 10.1016/j.ejphar.2015.06.026. Epub 2015 Jun 17. Review.

PMID:
26093041
45.

Design, Synthesis, and Evaluation of Thyronamine Analogues as Novel Potent Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists.

Chiellini G, Nesi G, Digiacomo M, Malvasi R, Espinoza S, Sabatini M, Frascarelli S, Laurino A, Cichero E, Macchia M, Gainetdinov RR, Fossa P, Raimondi L, Zucchi R, Rapposelli S.

J Med Chem. 2015 Jun 25;58(12):5096-107. doi: 10.1021/acs.jmedchem.5b00526. Epub 2015 Jun 5.

PMID:
26010728
46.

Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.

Urs NM, Bido S, Peterson SM, Daigle TL, Bass CE, Gainetdinov RR, Bezard E, Caron MG.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):E2517-26. doi: 10.1073/pnas.1502740112. Epub 2015 Apr 27.

47.

The trace amine-associated receptor 1 modulates methamphetamine's neurochemical and behavioral effects.

Cotter R, Pei Y, Mus L, Harmeier A, Gainetdinov RR, Hoener MC, Canales JJ.

Front Neurosci. 2015 Feb 13;9:39. doi: 10.3389/fnins.2015.00039. eCollection 2015.

48.

TAAR1 Modulates Cortical Glutamate NMDA Receptor Function.

Espinoza S, Lignani G, Caffino L, Maggi S, Sukhanov I, Leo D, Mus L, Emanuele M, Ronzitti G, Harmeier A, Medrihan L, Sotnikova TD, Chieregatti E, Hoener MC, Benfenati F, Tucci V, Fumagalli F, Gainetdinov RR.

Neuropsychopharmacology. 2015 Aug;40(9):2217-27. doi: 10.1038/npp.2015.65. Epub 2015 Mar 9.

49.

Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1.

Espinoza S, Ghisi V, Emanuele M, Leo D, Sukhanov I, Sotnikova TD, Chieregatti E, Gainetdinov RR.

Neuropharmacology. 2015 Jun;93:308-13. doi: 10.1016/j.neuropharm.2015.02.010. Epub 2015 Feb 24.

PMID:
25721394
50.

Dopamine receptors - IUPHAR Review 13.

Beaulieu JM, Espinoza S, Gainetdinov RR.

Br J Pharmacol. 2015 Jan;172(1):1-23. Review.

Supplemental Content

Loading ...
Support Center